Articles On Imugene (ASX:IMU)

Imugene Limited (ASX: IMU) shares have jumped by 5% in trading so far today after the biotechnology company announced it has completed recruitment for its HER-Vaxx Phase-2 gastric cancer trial. At the time of writing, the Imugene share pri...

ShareCafeAustralia…One Hour In…ASX up 85 points ASX200 up 85 points (1.3%) to 6692. Market tracking better on prospects for more US stimulus after the Democrats won control of the Senate.  Disturbingly,  the focus this morning has been on t...

The Phase 2 trial represents a clinical proof-of-concept for HER-Vaxx to indicate that B-cell activating immunotherapy platform can induce clinically active antibody responses.

The Rhythm Biosciences Ltd (ASX:RHY) share price has rocketed over 640% for the past twelve-month period. From the beginning of November alone, the share price has soared over 355%.  For the past few weeks, we’ve been watching Rhythm Biosc...

Summary Imugene Limited (ASX:IMU) completes the enrolment of three patients under the first cohort under PD1-Vaxx Phase I clinical trial. Following the Phase I trial, a monotherapy optimal biological dose will be determined through a r...

The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.

Summary Imugene Limited (ASX:IMU) has received an R&D tax refund of ~$4.82 million under government’s R&D tax incentive. The tax incentive is expected to support Imugene in its commercial and clinical milestones. Imugene has r...

Receiving the $4,823,466 million in additional funding will further support the company's commercial and clinical milestones.

Bell Potter has raised its valuation of Imugene to 17 cents from 5 cents and has maintained its buy (speculative) recommendation.

Summary Imugene Limited (ASX:IMU) has dosed its first patient in PD1-Vaxx Phase 1 trial in Melbourne. An optimal biological dose as a monotherapy will be determined after review by Imugene’s Cohort Review Committee. Imugene intends to...

Sydney biotech company Imugene (ASX:IMU) says it has dosed its first patient with its drug candidate PD1-Vaxx, a checkpoint immunotherapy ... Read More The post First patient dosed with Imugene’s lung cancer drug candidate appeared first on...

ShareCafeAustralia…One Hour In…ASX up 33 points ASX200 up 33 points (0.5%) to 6551. AUB (-1.6%); will acquire 360 Underwriting Solutions for $127m. Collins Foods (+4.2%); 1H profit +15%.   Strong result. Domino’s Pizza (+11%); Investor Day...

The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.

Summary Imugene Limited (ASX:IMU) has recently shared promising interim data from its continuing Phase 2 trial of HER-Vaxx. The interim analysis results demonstrated that twice as many patients survived on the HER-Vaxx plus SOC chemoth...

The share price of biotechnology company Imugene Limited (ASX: IMU) has been on a tear this year. Imugene shares are up another 13% today at the time of writing, meaning the share price has soared over 300% in the year to date. With a marke...

The Imugene Ltd [ASX:IMU] share price is trading 15% higher at time of writing. Rising on the back of new news from the biotech’s phase 2 trial. In what is now just the latest leg up for the company in the past month... The post Imugene Sha...

The IDMC provided guidance that it is scientifically and ethically appropriate to reduce the overall number of patients required to complete the study, given the strong signal observed in the data.

Summary Imugene has received the US FDA IND approval to kick-start Phase 1 clinical trial of PD1-Vaxx in the US. The FDA approval enables Imugene to commence patient dosing and recruitment in its Phase 1 clinical trial in the US in non-...

ShareCafeAustralia…One Hour In…ASX Up 6 Points ASX200 up 6 points (0.1%) to 5933. – AMP (+8.6%); says the Ares takeover proposal implies a value of $1.85 a share. Trading @ $1.65.– IAG (-0.8%); CEO Mark Milliner to leave. Nick Hawkins new C...

US FDA approval of the IND allows Imugene to initiate patient recruitment and dosing in its USA Phase I clinical study in non-small cell lung cancer (NSCLC) patients.

ul> Post delivering a solid performance in the June 2020 quarter, Imugene Limited (ASX:IMU) has released another set of robust quarterly results for the September 2020 quarter. During the quarter, Imugene achieved several significant...

During the September quarter, the clinical-stage immuno-oncology company continued to progress clinical programs and remains well-funded to cater for an expected increase in expenditures.

The company is well-funded to deliver on commercial and clinical milestones including the development of CF33, PD1-Vaxx and HER-Vaxx treatments.

Summary Imugene has attained a core patent in the largest pharmaceutical market of the world. The patent protects its cancer growth factor immunotherapy platform, predominantly unique combination treatments that target members of the IG...

Imugene's oncolytic viruses are designed to infect, replicate in, and kill cancer cells, leaving healthy cells essentially unharmed.

02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth fa…

The company recently boosted its balance sheet with a $5.7 million underwriting agreement to support four continuing clinical programs - CF33, PD1, Vaxx and HER-Vaxx as well as provide funding for IP and milestone payments.

Summary Imugene has appointed Dr Rita Laeufle as its new Chief Medical Officer and a member of its executive leadership team. Dr Laeufle will lead the Company’s global clinical development, medical monitoring, and regulatory activities....

The company recently entered into an agreement to underwrite outstanding listed options which provides holders with an option to purchase shares in the company at 2.6 cents per share.

NSW-headquartered clinical stage immuno-oncology firm, Imugene Limited (ASX:IMU) has secured an underwriting agreement with Bell Potter Securities Limited with institutional investors to underwrite the balance of options not exercised by 30...

The agreement with Bell Potter further strengthens the company’s financial position building on the existing cash balance of $30.1 million as of June 30, 2020.

Summary Imugene has received first ethics approval in the US to start PD1-Vaxx’s Phase I trial. The approval has been granted to Hackensack University Medical Center, based in New Jersey USA. Imugene has planned to proceed with the sit...

Site activation and patient recruitment will proceed after FDA IND approval scheduled for the fourth quarter of 2020.

In a latest update, the biotech company Imugene Limited (ASX:IMU) has published its Annual Report for the year ended 30th June 2020 on the ASX. The financial year 2020 has been a remarkable one for Imugene, experiencing significant change a...

The stock of Australian clinical-stage immuno-oncology company, Imugene Limited (ASX:IMU) traded ~1.8 per cent higher on 21st August 2020 following the release of a significant update on PD1-Vaxx’s third ethics approval for Phase 1 trial....

The ethics approval represents the third independent review of PD1-Vaxx pre-clinical safety and efficacy data.

Summary Imugene received US FDA guidance on the development pathway for VAXinia (CF33-hNIS). FDA provided feedback on adaptive Phase 1 clinical development plans and non-clinical development pathway for VAXinia. The Company has initiat...

The FDA provided feedback on the non-clinical development pathway and adaptive phase one clinical development plans for VAXinia, IMU’s lead oncolytic virotherapy for treatment of solid tumours.

“We’re sorry.” Two words rarely heard from company boards, and even more rarely in annual reports. But Lev Mizikozsky, chairman of sunscreen seller Advance Nanotek (ASX:ANO), is a man who doesn’t trend the conventional path. Mizikovsky’s ap...

Last month, Imugene received Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx in Australia.

Clinical stage immuno-oncology company, Imugene Limited (ASX:IMU) marked an uptick of ~22.6 per cent to $0.065 on ASX following the release of its solid June quarterly results on 27 July 2020. As at 11:50 AM AEST on 29 July 2020, IMU is tra...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Scott Powe...

Summary Imugene has received a second human research ethics approval to kickstart its Phase I clinical trial of PD1- Vaxx in Australia. While the second ethics approval has been received by Sydney-based Macquarie University, Chris O’Bri...

Immuno-oncology company Imugene (ASX: IMU) received a timely regulatory boost courtesy of a second Human Research Ethics Committee (HREC) approval to commence a Phase I clinical trial of its checkpoint immunotherapy candidate PD1-Vaxx, in A...

The ethics approval represents the second independent review of PD-1 Vaxx pre-clinical safety and efficacy.